Loading stock data…
TNGX
$20.98-0.64 (-2.96%)
Market ClosedLast close May 1
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tango Therapeutics, Inc. in the Healthcare sector is trading at $20.98. The stock is currently 26% below its 52-week high of $28.41, remaining 83.7% above its 200-day moving average. Technical signals show neutral RSI of 48 and bearish MACD signal, explaining why TNGX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$20.98
Potential Upside
5%
Whystock Fair Value$22.03
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$23.90+13.9%
Range$16.00 – $40.00
Fundamentals
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.89B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.31
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-42.05%
Volume
Today's trading volume
3.00M
Recent News
Why This CEO Is Confident His Drug Can Top 'Unprecedented' Pancreatic Cancer Results
Tango Therapeutics stock has soared this year on its pancreatic cancer treatment combination with Revolution Medicines.
Does Erasca (ERAS) Expanding ERAS-0015 to China Recast Its Global Oncology Ambitions?
Erasca recently expanded its worldwide rights to develop and commercialize its solid tumor candidate ERAS-0015 into China, Hong Kong, and Macau, and entered a collaboration and supply agreement with Tango Therapeutics to test ERAS-0015 in combination with vopimetostat. This combination of broader geographic rights and a partnered combination-therapy study highlights how Erasca is working to increase the potential reach and versatility of its oncology pipeline. We’ll now examine how the...
Is Tango Therapeutics (TNGX) Building the Right Leadership Mix to Navigate Complex Oncology Pipelines?
Tango Therapeutics has announced several leadership changes, appointing Matthew Gall as Chief Financial Officer, Yen-Ching Chua as Chief Development Operations Officer effective June 1, 2026, and Janice Kapty as SVP of Corporate Strategy and Project Leadership to guide clinical, operational and portfolio execution. An interesting aspect of these appointments is how the combined financial, clinical operations and portfolio expertise is being aligned around advancing vopimetostat and other...
Erasca (ERAS) Climbs 390% YTD on ‘Best-in-Class’ Potential of Cancer Treatment
Erasca Inc. (NASDAQ:ERAS) is one of the 11 Stocks With 3x-5x Returns This Year. Erasca has seen its share prices soar by 390 percent year-to-date, as investors sought to increase their exposure in the company amid developments on its treatment candidate for solid tumors. Earlier in the year, Erasca Inc. (NASDAQ:ERAS) expanded its worldwide rights […]
Tango Therapeutics President Sells 27,000 Shares for $572,000 as Share Price Skyrockets
This precision oncology developer reported a notable insider sale during a period of robust share price gains.